Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12084224rdf:typepubmed:Citationlld:pubmed
pubmed-article:12084224lifeskim:mentionsumls-concept:C0017296lld:lifeskim
pubmed-article:12084224lifeskim:mentionsumls-concept:C0042077lld:lifeskim
pubmed-article:12084224lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:12084224pubmed:issue1lld:pubmed
pubmed-article:12084224pubmed:dateCreated2002-6-26lld:pubmed
pubmed-article:12084224pubmed:abstractTextEffective treatments are needed urgently for metastatic disease in bladder, prostate, and renal cell cancer. In the past few years, several new approaches for treating these conditions have been proposed, including gene therapy. A number of different strategies have been developed to accomplish urologic cancer gene therapy. Genetic immunomodulation strategies attempt to activate immune defense mechanisms against tumor cells by transfer of tumor antigens, cytokine genes, or strongly immunogenic cell surface molecules. In this review, we illustrate the recent developments in immune gene therapy.lld:pubmed
pubmed-article:12084224pubmed:languageenglld:pubmed
pubmed-article:12084224pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12084224pubmed:citationSubsetIMlld:pubmed
pubmed-article:12084224pubmed:statusMEDLINElld:pubmed
pubmed-article:12084224pubmed:monthFeblld:pubmed
pubmed-article:12084224pubmed:issn1527-2737lld:pubmed
pubmed-article:12084224pubmed:authorpubmed-author:RatliffTimoth...lld:pubmed
pubmed-article:12084224pubmed:authorpubmed-author:BöhleAndreasAlld:pubmed
pubmed-article:12084224pubmed:authorpubmed-author:ArdeltPeterPlld:pubmed
pubmed-article:12084224pubmed:authorpubmed-author:KauschIngoIlld:pubmed
pubmed-article:12084224pubmed:issnTypePrintlld:pubmed
pubmed-article:12084224pubmed:volume3lld:pubmed
pubmed-article:12084224pubmed:ownerNLMlld:pubmed
pubmed-article:12084224pubmed:authorsCompleteYlld:pubmed
pubmed-article:12084224pubmed:pagination82-9lld:pubmed
pubmed-article:12084224pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:meshHeadingpubmed-meshheading:12084224...lld:pubmed
pubmed-article:12084224pubmed:year2002lld:pubmed
pubmed-article:12084224pubmed:articleTitleImmune gene therapy in urology.lld:pubmed
pubmed-article:12084224pubmed:affiliationDepartment of Urology, Medical University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.lld:pubmed
pubmed-article:12084224pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12084224pubmed:publicationTypeReviewlld:pubmed